May 17, 2020

Medline, Teleflex ink pact to distribute Rüsch brand of specialty urological products

Rüsch brand of specialty urological products
largest p
Admin
1 min
Medline Ind , Teleflex ink pact to distribute Rüsch brand of specialty urological products
Manufacturer and distributor of medical and surgical supplies,Medline Industries, Inc has entered into a strategic deal with Teleflex Incorporated to d...

Manufacturer and distributor of medical and surgical supplies, Medline Industries, Inc has entered into a strategic deal with Teleflex Incorporated to distribute its Rüsch brand of specialty urological products.

The deal with Teleflex will enable Medline’s 1,100 person sales force to sell and market the Rüsch brand of bladder management products throughout U.S.

Benson Smith, Teleflex Incorporated Chairman, President and CEO said, “This is an ideal arrangement matching our high quality urological products with Medline’s world-class sales force and marketing expertise.” “Partnering with Medline provides us with a very large and exciting opportunity to grow this segment of our business,” said, Mr. Smith.

 The products in the agreement include urinary drainage devices such as Foley and intermittent catheters, as well as specialty items for operative urology and endourology.

Charlie Mills, Medline CEO said, “Teleflex and Rüsch have a reputation for high-end, high quality urological products and this agreement enables us to expand our presence in the operating room and in other health care markets with these surgical and personal preference items.”

Teleflex is a global provider of specialty medical devices for a wide range of procedures in critical care and surgery. Medline is the largest privately held manufacturer and distributor of healthcare products. It distributes and manufactures more than 125,000 products to hospitals, extended care units, physician offices, and homecare dealers.

Share article

Jun 22, 2021

Bachem turns 50 - a timeline

pharma
supplychain
peptides
medication
3 min
As Bachem turns 50, we take a look at the company's history

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.  

1971 - beginnings

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes. 

1977 - 1981 - early growth

Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150. 

 1987 - 1996 - worldwide expansion

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988. 

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance. 

 1998 - 2003 - Bachem goes public

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and  Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients.  By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day. 

2007 - 2013 - acquisitions

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services. 

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion. 

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas. 

2016 - 2019 - a global leader

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K. 

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future. 

2020 - COVID-19

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and  272 new employees are hired.  

2021 - a milestone anniversary

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it  remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are  plans to continue expanding. 

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Share article